06/12/2018 15:14:14

Beyond Celiac partners with imaware™ to expand use of at-home celiac disease testing for faster medical diagnosis

Philadelphia, PA, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Beyond Celiac today announced their newest partner, imaware™.  imaware™ is a unique at-home celiac disease screening and monitoring test that is highly accurate and provides actionable results for patients. Beyond Celiac is partnering with imaware™ to support the ambitious goal of dramatically reducing the number of individuals dealing with undiagnosed celiac disease by helping them more quickly take the steps needed for diagnosis.

“Celiac disease has long been plagued by low diagnosis rates. It is estimated that less than 20 percent of patients who have the condition know it,” noted Alice Bast, Beyond Celiac CEO. “We hear from our community that their doctors do not want to test them despite symptoms. The average delay in diagnosis is 6 to 10 years. It took me eight years to get diagnosed,” she added.

A study published recently in the United European Gastroenterology Journal concluded that patients whose diagnosis had been delayed for three years reported being sick more often, going to the doctor more frequently and using more drugs for indigestion and depression than those who were diagnosed more quickly.

“We believe that the imaware™ at-home celiac disease test will help reduce the number of undiagnosed people with celiac disease,” said Jani Tuomi, Chief Product Officer for imaware™. “An easy to use test, with easy to read results that are reviewed by a doctor, will dramatically reduce time to diagnosis. With a partner like Beyond Celiac, we will be able to better engage with the patient community to educate, screen, and ultimately help patients engage their doctors sooner for diagnosis.”

The imaware™ test measures the same antibodies to gluten as the tests that doctors use in their offices as the first step to diagnose celiac disease – anti-tissue transglutaminase (tTG) and deaminated gliadin peptide (DGP) tests. In the United States, definitive diagnosis of celiac disease requires a biopsy that shows intestinal damage in addition to the blood test.

Sold online only, the imaware™ test requires a finger prick and collection of a small amount of blood in a vial. Consumers then mail their sample back and receive their confidential test results via a secure portal in about a week. For results to be accurate, consumers need to be on a normal gluten-containing diet. The imaware™ at-home test for celiac disease is available at imaware.health for $165.00. Beyond Celiac will receive a portion of sales to support their ongoing initiatives to drive diagnosis, advance research and accelerate the discovery of new treatments and a cure. 

XXX

About Celiac Disease

Celiac disease is a serious, genetic, autoimmune disorder that affects an estimated 1 in 100 Americans, the vast majority of whom are still undiagnosed. The disease causes debilitating symptoms, and if left untreated, can lead to serious long-term health problems including infertility and some types of cancer.

About Beyond Celiac:

A 501(c)(3) non-profit organization, Beyond Celiac envisions a world in which people with celiac disease can live healthy lives free from social stigma and fear of gluten exposure – A world Beyond Celiac.

Attachment

Claire Baker

Beyond Celiac

215-325-1306 ext. 111

cbaker@beyondceliac.org

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
12 Feb
VELO
Hvis agendaen er at komme i en god position for en samlet overtagelse - er de vel godt på vej. I hve..
31
13 Feb
VELO
Her er nogle spørgsmål som jeg ønsker besvaret. Håber i andre vil bidrage med flere spørgsmål som JP..
24
12 Feb
PNDORA
Uden at skulle fremsætte nogen konspirationsteorier så finder jeg det personligt ganske interasant a..
23
12 Feb
GOMX
I får det seriøst til at lyde somom GomX er på vej ned og snakker dommedag 😂! Hallo bois!! Det førs..
20
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
18
11 Feb
VWS
MHI Vestas named as Preferred Supplier for 476 MW Baltic Eagle project in Germany http://www.mhivest..
18
12 Feb
PNDORA
Fuldstændig uenig.Noget af Pandoras fald er absolut berettiget, ingen tvivl om det!   MEN.Pandora ha..
16
11 Feb
DSV
Der er nogen i denne her tråd, der burde skamme sig, og derefter lære at holde deres ubegavede ringe..
15
14 Feb
PNDORA
Jeg vædder hermed håneretten på, at det værste i Pandora er overstået. Jeg synes, at kunne fornem..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
CLASS ACTION UPDATE for UXIN, WRCDF, WCAGY and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
2
CLASS ACTION UPDATE for XRAY, NVDA, AGN and YRIV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
3
CLASS ACTION UPDATE for IMMU, DBVT, MU and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
4
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of YRCW, TYME, UXIN and TAP
5
CLASS ACTION UPDATE for AXGN, TYME and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 February 2019 03:10:10
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB3 - 2019-02-18 04:10:10 - 2019-02-18 03:10:10 - 1000 - Website: OKAY